Back to results
US 11,078,205 B2Granted
Selective inhibitors of protein arginine methlytransferase 5 (PRMT5)
AssigneePrelude Therapeutics Incorporated
InventorsHong Lin, Juan Luengo, Rupa Shetty, Michael Hawkins
Life of this patent
Estimating the term…
Abstract
The disclosure is directed to compounds of Formula I Pharmaceutical compositions comprising compounds of Formula I, as well as methods of their use and preparation, are also described.
Claims26
A compound of Formula I:
- or a pharmaceutically acceptable salt or solvate thereof;
- wherein
- R1 is —C0-C6alk-C1-C6alkyl, —C0-C6alk-C1-C6haloalkyl, —C1-C6alk-O—C1-C6alkyl, —C1-C6alk-S—C1-C6alkyl, —C1-C6alk-S—C1-C6alk-CO2H, —C1-Chalk-aryl, —C1-C6alk-O-aryl, —C1-C6alk-NH-aryl, —C1-C6alk-S-aryl, —C0-C6alk-heteroaryl, —C1-C6alk-O-heteroaryl, —C1-C6alk-S-heteroaryl, —C1-C6alk-NH-heteroaryl, or —C(O)NH-aryl;
- R2 is —C1-C6alkyl, —C1-C6haloalkyl, —C2-C6alkenyl, or —C2-C6alkynyl;
- R3 is H, halo, NH2, or —C1-C6alkyl;
- R4 is H, halo, —C1-C6alkyl, —C1-C6alk-O—C1-C6alkyl, —NR6R6′, —NHCONR6R6′, —NHC(S)NR6R6′, —NH—O—R6, or —NH—NR6R6′;
- R5 is H, halo, —C1-C6alkyl, —C1-C6haloalkyl, —C2-C6alkenyl, —C2-C6alkynyl, or —C1-C6alk-OH;
- and
- R6 and R6′ are each independently H, C1-C6alkyl, or —C1-C6alk-OC1-C6alkyl;
- or R6 and R6′, together with the atom to which they are attached, form a C3-C6heterocycloalkyl ring.
7 more elements
Dependencies are inferred from the claim text.